PFIZER INC.

Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer to lead clinical strategy and execution for its targeted cancer therapy pipeline.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

Lantheus Holdings announced its participation in the FIBRE Consortium alongside Pfizer and Lumina Pharmaceuticals to revolutionize fibrotic disease treatment through advanced imaging biomarkers.

The newly appointed Advisory Committee on Immunization Practices (ACIP) voted 5-1 to recommend thimerosal-free influenza vaccines for all age groups, despite the preservative being present in only 6% of U.S. flu vaccines.

Liminatus Pharma's IBA101, a second-generation CD47 inhibitor, demonstrated strong safety profile in primate studies with no observed anemia or thrombocytopenia at doses up to 100 mg/kg/week.

The BRACELET-1 trial demonstrated that pelareorep combined with paclitaxel achieved a 31% objective response rate and 12.1-month median progression-free survival in HR+ HER2- metastatic breast cancer patients.

Perceptive Discovery announced the launch of the FIBRE Consortium, a pre-competitive collaboration with Pfizer, Lantheus, and Lumina Pharmaceuticals to revolutionize multi-organ fibrotic disease treatment through advanced imaging biomarkers.

Avalo Therapeutics has appointed Rita Jain, M.D., a rheumatologist with over two decades of biopharmaceutical leadership experience, to its Board of Directors.

Solu Therapeutics has appointed Enda Moran, PhD, MBA as Chief Operating Officer to lead operational functions as the company advances its Phase 1 clinical trial of STX-0712.

UCLA Health researchers analyzed 3,500 hospitalized COVID-19 patients and found unvaccinated individuals were 16% more likely to require continuous renal replacement therapy during hospitalization.